fiverr one

Newswire

[ March 6, 2025 ] Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer Newsmakers
[ March 3, 2025 ] BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia Newsmakers
[ February 24, 2025 ] PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights Newsmakers
[ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
[ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
[ February 5, 2025 ] Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Newsmakers
[ February 5, 2025 ] Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Newsmakers
[ January 30, 2025 ] BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG) Newsmakers
[ January 30, 2025 ] ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation Newsmakers
[ January 30, 2025 ] Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Newsmakers

Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

March 6, 2025 Comments Off on Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the [...]
BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

March 3, 2025 Comments Off on BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia
PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

February 24, 2025 Comments Off on PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas

February 18, 2025 Comments Off on ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas
ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

February 18, 2025 Comments Off on ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

March 6, 2025 Comments Off on Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

HOUSTON, March 06, 2025 — Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the [...]
Post 2

February 9, 2009 Comments Off on Post 2
Palm(NASDAQ: PALM) builds momentum;

February 9, 2009 Comments Off on Palm(NASDAQ: PALM) builds momentum;
Post 4

February 9, 2009 Comments Off on Post 4
Value Investing Opportunities (Prospect List Here)

February 10, 2009 Comments Off on Value Investing Opportunities (Prospect List Here)

Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

March 6, 2025 Comments Off on Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

March 3, 2025 Comments Off on BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia
PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

February 24, 2025 Comments Off on PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights
ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas

February 18, 2025 Comments Off on ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas
ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

February 18, 2025 Comments Off on ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

February 5, 2025 Comments Off on Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Get Your Share of the $31 BILLION Watch Market!

June 24, 2024 Comments Off on Get Your Share of the $31 BILLION Watch Market!
Snow Lake (NASDAQ: LITM) Expanding Lithium Resource w M&A Pipeline

November 6, 2023 Comments Off on Snow Lake (NASDAQ: LITM) Expanding Lithium Resource w M&A Pipeline
Appia Rare Earths & Uranium (OTC: APAAF)”Incredible Drilling Results” at Brazil Rare Earths Project

November 6, 2023 Comments Off on Appia Rare Earths & Uranium (OTC: APAAF)”Incredible Drilling Results” at Brazil Rare Earths Project
Snow Lake Lithium (NASDAQ: LITM) Supplying Lithium for EV Boom!

October 5, 2023 Comments Off on Snow Lake Lithium (NASDAQ: LITM) Supplying Lithium for EV Boom!
Stria Resources (OTC: SRCAF) LITHIUM RESOURCE = “Multi Bagger” UPSIDE Potential

August 22, 2023 Comments Off on Stria Resources (OTC: SRCAF) LITHIUM RESOURCE = “Multi Bagger” UPSIDE Potential
Lithium EV Battery Metals w “MULTI-BAGGER” Upside Potential! Stria (OTC: SRCAF)

July 15, 2023 Comments Off on Lithium EV Battery Metals w “MULTI-BAGGER” Upside Potential! Stria (OTC: SRCAF)
NEXT SUPER STOCK Nova Mentis Life Sciences (OTC: NMLSF)Psilocybin for Autism FXS – Patient Enrollment for Phase 2A Clinical Trials

April 5, 2023 Comments Off on NEXT SUPER STOCK Nova Mentis Life Sciences (OTC: NMLSF)Psilocybin for Autism FXS – Patient Enrollment for Phase 2A Clinical Trials
Stria Lithium (OTC: SRCAF) (TSX: SRA): LITHIUM Powering the EV Revolution!

March 17, 2023 Comments Off on Stria Lithium (OTC: SRCAF) (TSX: SRA): LITHIUM Powering the EV Revolution!

Get Your Share of the $31 BILLION Watch Market!

June 24, 2024 Comments Off on Get Your Share of the $31 BILLION Watch Market!
Snow Lake (NASDAQ: LITM) Expanding Lithium Resource w M&A Pipeline

November 6, 2023 Comments Off on Snow Lake (NASDAQ: LITM) Expanding Lithium Resource w M&A Pipeline
Appia Rare Earths & Uranium (OTC: APAAF)”Incredible Drilling Results” at Brazil Rare Earths Project

November 6, 2023 Comments Off on Appia Rare Earths & Uranium (OTC: APAAF)”Incredible Drilling Results” at Brazil Rare Earths Project
Snow Lake Lithium (NASDAQ: LITM) Supplying Lithium for EV Boom!

October 5, 2023 Comments Off on Snow Lake Lithium (NASDAQ: LITM) Supplying Lithium for EV Boom!
Stria Resources (OTC: SRCAF) LITHIUM RESOURCE = “Multi Bagger” UPSIDE Potential

August 22, 2023 Comments Off on Stria Resources (OTC: SRCAF) LITHIUM RESOURCE = “Multi Bagger” UPSIDE Potential
Lithium EV Battery Metals w “MULTI-BAGGER” Upside Potential! Stria (OTC: SRCAF)

July 15, 2023 Comments Off on Lithium EV Battery Metals w “MULTI-BAGGER” Upside Potential! Stria (OTC: SRCAF)
“The $AMZN of Africa” Jumia Technologies (NYSE: JMIA) CEO Interview w Francis Dufay

June 9, 2023 Comments Off on “The $AMZN of Africa” Jumia Technologies (NYSE: JMIA) CEO Interview w Francis Dufay
NEXT SUPER STOCK Nova Mentis Life Sciences (OTC: NMLSF)Psilocybin for Autism FXS – Patient Enrollment for Phase 2A Clinical Trials

April 5, 2023 Comments Off on NEXT SUPER STOCK Nova Mentis Life Sciences (OTC: NMLSF)Psilocybin for Autism FXS – Patient Enrollment for Phase 2A Clinical Trials

Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.